Model-based cost-effectiveness analysis (secondary analysis of LIGHTSITE III data) in intermediate dry AMD: photobiomodulation vs no treatment gave a base-case ICER of $73,910/QALY over 10 years, below US thresholds; 5-year US budget impact $25.0 billion at 20% uptake.
Secondary analysis
Watane et al. Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial